Alopexx Partners with Bharat Biotech to Co-Develop and Commercialize AV0328 Anti-Microbial Vaccine
Shots:
- Alopexx and Bharat Biotech have partnered to co-develop & commercialize the former’s AV0328, a broad-spectrum anti-microbial vaccine, across India as well as other low income & lower middle-income countries
- Bharat Biotech will pay one-time upfront, milestones as well as sales-based royalties linked to AV0328 in the licensed territories
- AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), was effective against 15 distinct pathogens in preclinical study and well-tolerated in P-I study without any SAEs. It produced antibodies that effectively killed a variety of PNAG-expressing pathogens, showing promise as a broad-spectrum antimicrobial solution
Ref: Globenewswire | Image: Alopexx & Bharat Biotech
Related News: Bharat Biotech Reports Results of Covaxin (BBV152) in P-II/III Trial for the Treatment of COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
